Statement under clause 13(3) of SEBI (LODR) Regulations 2015, for the quarter ended on 31st December, 2015:

Particulars	31/12/2015
INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	Nil
Received during the quarter	10
Disposed of during the quarter	10
Remaining unresolved at the end of the	Nil
quarter	

For Jenburkt Pharmaceuticals Ltd.
For JENBURKT PHARMACEUTICALS LTD.

ASHISH R. SHAH
ASHISH R. SHAH
12-01-16

Company Secretary & Compliance Officer.